Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate Pre-Exposure Prophylaxis (PrEP) levels in
transgender-identifying or gender non-binary individuals taking versus not taking gender
affirming hormone therapy. Subjects who have previously taken F/TDF as PrEP will continue
with a fixed dose combination of daily oral F/TAF substituting for F/TDF. Subjects will
receive the iTAB text messaging adherence reminders to provide personalized, automated text
messages to support and monitor adherence that will vary by participant choice until 12 weeks
after switching medication. This study will enroll 60 individuals to take F/TAF as PrEP for
48 weeks.